

SEQUENCE LISTING

<110> Marks, Daniel L.
Cone, Roger D.

<120> Methods and Reagents for Discovering and Using
Mammalian Melanocortin Receptor Antagonists to Treat
Cachexia

<130> 96-886

<140> 08/706,281

<141> 1996-09-04

<160> 10

<170> PatentIn Ver. 2.0

<210> 1

<211> 1671

<212> DNA

<213> Homo sapiens

<220>

<221> CDS

<222> (394)..(1389)

<400> 1

```

agcttccgag aggcagccga tgtgagcatg tgcgcacaga ttcgtctccc aatggcatgg 60
cagcttcaag gaaaattatt ttgaacagac ttgaatgcat aagattaaag tttaaagcaga 120
agtgagaaca agaaagcaaa gagcagactc tttcaactga gaatgaatat tttgaagccc 180
aagatttttaa cgtgatgatg attagagtcg tacctaaaag agactaaaaa ctccatgtca 240
agctctggac ttgtgacatt tactcacagc aggcattggca attttagcct cacaactttc 300
agacagataa agacttggag gaaataactg agacgactcc ctgaccagg aggttaaadc 360
aattcagggg gacactggaa ttctcctgcc agc atg gtg aac tcc acc cac cgt 414
                               Met Val Asn Ser Thr His Arg
                               1           5

ggg atg cac act tct ctg cac ctc tgg aac cgc agc agt tac aga ctg 462
Gly Met His Thr Ser Leu His Leu Trp Asn Arg Ser Ser Tyr Arg Leu
          10           15           20

cac agc aat gcc agt gag tcc ctt gga aaa ggc tac tct gat gga ggg 510
His Ser Asn Ala Ser Glu Ser Leu Gly Lys Gly Tyr Ser Asp Gly Gly
          25           30           35

tgc tac gcg caa ctt ttt gtc tct cct gag gtg ttt gtg act ctg ggt 558
Cys Tyr Ala Gln Leu Phe Val Ser Pro Glu Val Phe Val Thr Leu Gly
          40           45           50           55

gtg atc agc ttg ttg gag aat atc tta gag att gtg gca ata gcc aag 606

```

Val	Ile	Ser	Leu	Leu	Glu	Asn	Ile	Leu	Glu	Ile	Val	Ala	Ile	Ala	Lys	
				60					65						70	
aac	aag	aat	ctg	cat	tca	ccc	atg	tac	ttt	ttc	atc	tgc	agc	ttg	gct	654
Asn	Lys	Asn	Leu	His	Ser	Pro	Met	Tyr	Phe	Phe	Ile	Cys	Ser	Leu	Ala	
			75					80					85			
gtg	gct	gat	atg	ctg	gtg	agc	gtt	tca	aat	gga	tca	gaa	acc	att	atc	702
Val	Ala	Asp	Met	Leu	Val	Ser	Val	Ser	Asn	Gly	Ser	Glu	Thr	Ile	Ile	
		90					95					100				
atc	acc	cta	tta	aac	cgt	aca	gat	acg	gat	gca	cag	agt	ttc	aca	gtg	750
Ile	Thr	Leu	Leu	Asn	Arg	Thr	Asp	Thr	Asp	Ala	Gln	Ser	Phe	Thr	Val	
	105					110					115					
aat	att	gat	aat	gtc	att	gac	tcg	gtg	atc	tgt	agc	tcc	ttg	ctt	gca	798
Asn	Ile	Asp	Asn	Val	Ile	Asp	Ser	Val	Ile	Cys	Ser	Ser	Leu	Leu	Ala	
120				125						130					135	
tcc	att	tgc	agc	ctg	ctt	tca	att	gca	gtg	gac	agg	tac	ttt	act	atc	846
Ser	Ile	Cys	Ser	Leu	Leu	Ser	Ile	Ala	Val	Asp	Arg	Tyr	Phe	Thr	Ile	
				140					145					150		
ttc	tat	gct	ctc	cag	tac	cat	aac	att	atg	aca	gtt	aag	cgg	gtt	ggg	894
Phe	Tyr	Ala	Leu	Gln	Tyr	His	Asn	Ile	Met	Thr	Val	Lys	Arg	Val	Gly	
			155					160					165			
atc	agc	ata	agt	tgt	atc	tgg	gca	gct	tgc	acg	gtt	tca	ggg	att	ttg	942
Ile	Ser	Ile	Ser	Cys	Ile	Trp	Ala	Ala	Cys	Thr	Val	Ser	Gly	Ile	Leu	
		170					175					180				
ttc	atc	att	tac	tca	gat	agt	agt	gct	gtc	atc	atc	tgc	ctc	atc	acc	990
Phe	Ile	Ile	Tyr	Ser	Asp	Ser	Ser	Ala	Val	Ile	Ile	Cys	Leu	Ile	Thr	
	185					190					195					
atg	ttc	ttc	acc	atg	ctg	gct	ctc	atg	gct	tct	ctc	tat	gtc	cac	ctg	1038
Met	Phe	Phe	Thr	Met	Leu	Ala	Leu	Met	Ala	Ser	Leu	Tyr	Val	His	Leu	
200					205					210					215	
ttc	ctg	atg	gcc	agg	ctt	cac	att	aag	agg	att	gct	gtc	ctc	ccc	ggc	1086
Phe	Leu	Met	Ala	Arg	Leu	His	Ile	Lys	Arg	Ile	Ala	Val	Leu	Pro	Gly	
				220					225					230		
act	ggg	gcc	atc	cgc	caa	ggg	gcc	aat	atg	aag	gga	gcg	att	acc	ttg	1134
Thr	Gly	Ala	Ile	Arg	Gln	Gly	Ala	Asn	Met	Lys	Gly	Ala	Ile	Thr	Leu	
			235					240					245			
acc	atc	ctg	att	ggc	gtc	ttt	gtt	gtc	tgc	tgg	gcc	cca	ttc	ttc	ctc	1182
Thr	Ile	Leu	Ile	Gly	Val	Phe	Val	Val	Cys	Trp	Ala	Pro	Phe	Phe	Leu	
		250					255					260				
cac	tta	ata	ttc	tac	atc	tct	tgt	cct	cag	aat	cca	tat	tgt	gtg	tgc	1230
His	Leu	Ile	Phe	Tyr	Ile	Ser	Cys	Pro	Gln	Asn	Pro	Tyr	Cys	Val	Cys	
	265					270					275					
ttc	atg	tct	cac	ttt	aac	ttg	tat	ctc	ata	ctg	atc	atg	tgt	aat	tca	1278
Phe	Met	Ser	His	Phe	Asn	Leu	Tyr	Leu	Ile	Leu	Ile	Met	Cys	Asn	Ser	

Val Asp Arg Tyr Phe Thr Ile Phe Tyr Ala Leu Gln Tyr His Asn Ile
 145 150 155 160
 Met Thr Val Lys Arg Val Gly Ile Ser Ile Ser Cys Ile Trp Ala Ala
 165 170 175
 Cys Thr Val Ser Gly Ile Leu Phe Ile Ile Tyr Ser Asp Ser Ser Ala
 180 185 190
 Val Ile Ile Cys Leu Ile Thr Met Phe Phe Thr Met Leu Ala Leu Met
 195 200 205
 Ala Ser Leu Tyr Val His Leu Phe Leu Met Ala Arg Leu His Ile Lys
 210 215 220
 Arg Ile Ala Val Leu Pro Gly Thr Gly Ala Ile Arg Gln Gly Ala Asn
 225 230 235 240
 Met Lys Gly Ala Ile Thr Leu Thr Ile Leu Ile Gly Val Phe Val Val
 245 250 255
 Cys Trp Ala Pro Phe Phe Leu His Leu Ile Phe Tyr Ile Ser Cys Pro
 260 265 270
 Gln Asn Pro Tyr Cys Val Cys Phe Met Ser His Phe Asn Leu Tyr Leu
 275 280 285
 Ile Leu Ile Met Cys Asn Ser Ile Ile Asp Pro Leu Ile Tyr Ala Leu
 290 295 300
 Arg Ser Gln Glu Leu Arg Lys Thr Phe Lys Glu Ile Ile Ser Ser Tyr
 305 310 315 320
 Pro Leu Gly Gly Leu Cys Asp Leu Ser Ser Arg Tyr
 325 330

<210> 3

<211> 35

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: degenerate
oligonucleotide primer

<220>

<221> misc_feature

<222> (23)..(24)

<223> "n" is inosine

<400> 3

gagtcgacct gtgygysaty rcnntkgacm gstac

35

<210> 4

<211> 32
<212> DNA
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: degenerate
oligonucleotide primer

<220>

<221> misc_feature
<222> (18)
<223> "n" is inosine

<400> 4

cagaattcag wagggcancc agcagasryg aa

32

<210> 5

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<221> SITE
<222> (1)
<223> "Xaa" is norleucine

<220>

<221> SITE
<222> (4)
<223> "Xaa" is naphthyl-D-alanine

<220>

<223> Description of Artificial Sequence: peptide
cyclized between the epsilon amino group of the
lysine and the sidechain carboxyl group of the
aspartic acid

<400> 5

Xaa Asp His Xaa Arg Trp Lys
1 5

<210> 6

<211> 30

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: degenerate
oligonucleotide primer

<400> 6

gaattcgacg tcacagtatg acggccatgg

30

<210> 7

<211> 48
<212> DNA
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:
oligonucleotide primer

<400> 7

aattagcgcc cgcagtatgc aaaaaaaagc ccgctcatta ggcgggct 48

<210> 8

<211> 48

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:
oligonucleotide primer

<400> 8

ccgaagcccg cctaattgagc gggctttttt ttgcatactg cggccgct 48

<210> 9

<211> 72

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:
oligonucleotide primer

<400> 9

ggccggcatg catcaagctt atctcgagat cgtcgactac catggtacat cgatcaggta 60

ccatcccggg gc 72

<210> 10

<211> 72

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:
oligonucleotide primer

<400> 10

ggccgccccg ggatggtacc tgatcgtatg accatggtag tcgacgatct cgagataagc 60

ttgatgcatg cc 72